Ventyx Biosciences (VTYX) News Today $1.66 -0.03 (-1.78%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.07 (+3.92%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025February 18 at 9:24 AM | markets.businessinsider.comVentyx Biosciences’ VTX958 shows efficacy in Crohn’s DiseaseFebruary 18 at 9:24 AM | markets.businessinsider.comVentyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025February 18 at 8:00 AM | globenewswire.comVentyx Biosciences (VTYX) Projected to Post Earnings on TuesdayVentyx Biosciences (NASDAQ:VTYX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 4:58 AM | marketbeat.comVentyx Biosciences stock hits 52-week low at $1.57February 12, 2025 | msn.comVentyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comShort Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Drops By 30.4%Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 6,680,000 shares, a decrease of 30.4% from the December 31st total of 9,600,000 shares. Based on an average daily volume of 1,750,000 shares, the short-interest ratio is presently 3.8 days. Currently, 12.6% of the shares of the stock are sold short.January 31, 2025 | marketbeat.comHC Wainwright Analysts Increase Earnings Estimates for VTYXVentyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Ventyx Biosciences in a research note issued on Tuesday, January 14th. HC Wainwright analyst E. Bodnar now expects that the company will earJanuary 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for VTYX FY2029 Earnings?Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Analysts at HC Wainwright issued their FY2029 earnings estimates for Ventyx Biosciences in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($1.34) forJanuary 16, 2025 | marketbeat.comVentyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. WainwrightJanuary 16, 2025 | markets.businessinsider.comVentyx Biosciences (VTYX) Gets a Hold from H.C. WainwrightJanuary 16, 2025 | markets.businessinsider.comVentyx Biosciences highlights its 2025 pipeline strategyJanuary 15, 2025 | finance.yahoo.comVentyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC WainwrightHC Wainwright restated a "neutral" rating on shares of Ventyx Biosciences in a research report on Tuesday.January 14, 2025 | marketbeat.comVentyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor PortfolioJanuary 14, 2025 | globenewswire.comWe're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn RateJanuary 10, 2025 | finance.yahoo.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 21,119 SharesDecember 31, 2024 | insidertrades.comInsider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells 21,119 Shares of StockVentyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $2.36, for a total value of $49,840.84. Following the completion of the sale, the insider now owns 464,582 shares in the company, valued at approximately $1,096,413.52. This trade represents a 4.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.December 30, 2024 | marketbeat.comHedge Fund and Insider Trading News: Warren Buffett, Bill Ackman, Ventyx Biosciences Inc (VTYX), Walmart Inc (WMT), and MoreDecember 29, 2024 | insidermonkey.comSheila Gujrathi Buys 130,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) StockVentyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) Director Sheila Gujrathi acquired 130,000 shares of the business's stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the transaction, the director now owns 130,000 shares in the company, valued at approximately $300,300. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.December 26, 2024 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 SharesVentyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) insider John Nuss sold 13,161 shares of the company's stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the sale, the insider now directly owns 485,701 shares in the company, valued at $1,097,684.26. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.December 19, 2024 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have assigDecember 17, 2024 | marketbeat.comVentyx Biosciences Insiders Land Bargain With Gains Of US$180kDecember 14, 2024 | finance.yahoo.comVENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmDecember 10, 2024 | globenewswire.comVestal Point Capital LP Purchases 410,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)Vestal Point Capital LP increased its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 31.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,725,000 shares of the company's stock after pNovember 29, 2024 | marketbeat.comSio Capital Management LLC Purchases 1,193,024 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)Sio Capital Management LLC raised its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 153.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,971,948 shares of the company's stock aftNovember 29, 2024 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Acquires 238,248 SharesNovember 26, 2024 | insidertrades.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Rating of "Moderate Buy" by AnalystsShares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the comNovember 22, 2024 | marketbeat.comVentyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measuresNovember 17, 2024 | finance.yahoo.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesNovember 12, 2024 | globenewswire.comVentyx Biosciences: Strong Financial Position and Promising Pipeline Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comVentyx Biosciences Reports Q3 Financial Results and Pipeline ProgressNovember 11, 2024 | tipranks.comVentyx Biosciences (VTYX) Receives a Buy from LifeSci CapitalNovember 9, 2024 | markets.businessinsider.comVentyx Biosciences (VTYX) Gets a Buy from OppenheimerNovember 9, 2024 | markets.businessinsider.comVentyx Biosciences' (VTYX) Outperform Rating Reaffirmed at OppenheimerOppenheimer reissued an "outperform" rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday.November 8, 2024 | marketbeat.comVentyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate ProgressNovember 8, 2024 | markets.businessinsider.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company.October 28, 2024 | marketbeat.comFY2024 EPS Estimates for Ventyx Biosciences, Inc. Cut by HC Wainwright (NASDAQ:VTYX)Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Ventyx Biosciences in a research report issued on Tuesday, October 15th. HC Wainwright analyst E. Bodnar now forecasts that the companyOctober 17, 2024 | marketbeat.comVentyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024October 16, 2024 | finance.yahoo.comVentyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $6.00 price target on shares of Ventyx Biosciences in a research note on Tuesday.October 15, 2024 | marketbeat.comVentyx Biosciences Inc VTYXOctober 10, 2024 | morningstar.comDeerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)Deerfield Management Company L.P. Series C lifted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 64.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,829,570 shares of theSeptember 26, 2024 | marketbeat.comEquities Analysts Set Expectations for Ventyx Biosciences, Inc.'s FY2024 Earnings (NASDAQ:VTYX)Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - HC Wainwright upped their FY2024 EPS estimates for shares of Ventyx Biosciences in a research note issued on Monday, September 23rd. HC Wainwright analyst E. Bodnar now expects that the company will earn ($2.13) per share for the year, up froSeptember 26, 2024 | marketbeat.comOppenheimer Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)September 24, 2024 | markets.businessinsider.comVentyx Biosciences (NASDAQ:VTYX) Stock Quotes, Forecast and News SummarySeptember 24, 2024 | benzinga.comVentyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical TrialsSeptember 24, 2024 | markets.businessinsider.comVentyx Biosciences Shares Rise Premarket on Sanofi InvestmentSeptember 23, 2024 | marketwatch.comVentyx Biosciences Announces $27 Million Strategic Investment from SanofiSeptember 23, 2024 | finance.yahoo.comAcadian Asset Management LLC Invests $608,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX)Acadian Asset Management LLC purchased a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 263,565 shares of the company's stock, valueSeptember 18, 2024 | marketbeat.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Given Consensus Rating of "Moderate Buy" by AnalystsVentyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have issued a buSeptember 8, 2024 | marketbeat.comVentyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s DiseaseSeptember 7, 2024 | markets.businessinsider.com Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address VTYX Media Mentions By Week VTYX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTYX News Sentiment▼-0.040.57▲Average Medical News Sentiment VTYX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTYX Articles This Week▼44▲VTYX Articles Average Week Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KalVista Pharmaceuticals News Today ProKidney News Today ABIVAX Société Anonyme News Today Organogenesis News Today Compass Therapeutics News Today Akebia Therapeutics News Today PureTech Health News Today Altimmune News Today ChromaDex News Today Kamada News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTYX) was last updated on 2/20/2025 by MarketBeat.com Staff From Our PartnersA new coin is elbowing its way to the top of the crypto worldWith Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
